PKI Stock Recent News

Revvity's (PKI) first-quarter results are likely to reflect weak performance at the Diagnostics segment, partially offset by strong demand for Life Sciences and Diagnostics franchise.

PerkinElmer (PKI) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

WALTHAM, Mass.--(BUSINESS WIRE)--The Board of Directors of PerkinElmer, Inc. (NYSE: PKI) today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on August 11, 2023 to all shareholders of record at the close of business on July 21, 2023. About The PerkinElmer Life Sciences and Diagnostics Company The PerkinElmer Life Sciences and Diagnostics company – which is to be renamed during the second quarter of 2023 – provides end-to-end solutions that hel.

PerkinElmer (PKI) completes separation of its businesses into two entities ??? the AES business, and the Life Sciences and Diagnostics business.

PerkinElmer's (PKI) latest launch is expected to provide increased assay flexibility to researchers.

PerkinElmer's (PKI) fourth-quarter results benefit from the solid performance of the Discover & Analytics Solutions business, more than offset by lower COVID-related sales.

PerkinElmer, Inc. (NYSE:PKI ) Q4 2022 Earnings Conference Call February 14, 2023 8:00 AM ET Company Participants Steve Willoughby - SVP, IR Prahlad Singh - President and CEO Max Krakowiak - SVP and CFO Conference Call Participants Derik de Bruin - Bank of America Patrick Donnelly - Citi Joshua Waldman - Cleveland Research Liza Garcia - UBS Dan Arias - Stifel Jack Meehan - Nephron Research Paul Knight - KeyBanc Max Masucci - Cowen Dan Leonard - Credit Suisse Matt Sykes - Goldman Sachs Rachel Vatnsdal - JPMorgan Vijay Kumar - Evercore ISI Operator Hello, and welcome to the PerkinElmer Fourth Quarter 2022 Earnings Conference Call. My name is Alex, and I'll be coordinating the call today.

PerkinElmer (PKI) delivered earnings and revenue surprises of 2.41% and 1.97%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

PerkinElmer continues to offer long-term upside potential with its management of capital and acquisitions. The economic value of its transactions has created a healthy return on investment over the time period.

PerkinElmer, Inc. (NYSE:PKI ) 41st Annual J.P. Morgan Healthcare Conference Call January 10, 2023 11:15 AM ET Company Participants Prahlad Singh - President and Chief Executive Officer Conference Call Participants Rachel Vatnsdal - JPMorgan Chase & Co. Rachel Vatnsdal Hi, everyone.